ReviewJournal of medical virology2026
Reverse Genetics of Orthoflaviviruses: Strategies for Constructing Functional or Infectious cDNA.
Review in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Reverse genetics (RG) systems have transformed RNA virus research by enabling the recovery of recombinant viruses entirely from cloned cDNA. These platforms allow precise, hypothesis-driven manipulation of viral genomes and support systematic phenotypic analyses in vitro and in vivo. Orthoflaviviruses, a genus that includes numerous zoonotic arboviruses associated with neurological and visceral disease, present distinct challenges for RG development. RNA-launched systems, which rely on in vitro transcription of infectious RNA from a full-length functional cDNA clone, have long been the standard approach. However, the technical demands of RNA synthesis and handling have increased interest in DNA-launched systems that initiate virus recovery directly from a full-length infectious cDNA clone. Despite these advances, constructing genetically stable full-length orthoflavivirus cDNA clones remains difficult because certain genomic regions are unstable or toxic during bacterial propagation. To address these obstacles, conventional bacteria-based cloning has been supplemented with bacteria-free strategies such as long-distance reverse transcription-PCR, circular polymerase extension reaction, Gibson isothermal assembly, and infectious subgenomic amplicons. This commentary summarizes the key features, strengths, and limitations of current RNA- and DNA-launched RG systems for orthoflaviviruses, with emphasis on the technical challenges unique to this group. Together, these perspectives provide a framework for selecting and implementing RG approaches tailored to orthoflaviviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.